We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


A Set Up to Sequence 280,000 Human Genomes Per Year

A Set Up to Sequence 280,000 Human Genomes Per Year content piece image
These are two NovaSeq instruments installed on-site. Credit: Novogene
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Novogene has announced the order of 25 Illumina NovaSeq 6000 sequencers. Five of the sequencers will be located in the U.S. In addition, Novogene will operate the 20 units purchased by Nanjing Yangzi State Owned Investment Group in China. With the addition of these new NovaSeq sequencers to its existing array of 30 Illumina HiSeq X and 10 PacBio Sequel systems, Novogene now offers the largest and most advanced sequencing capacity in the world with annual throughput of 280,000 human whole genomes.

The addition of the NovaSeq sequencers not only expands Novogene’s sequencing capacity, but also greatly reduces its sequencing cycle times. With NovaSeq, Novogene will be able to sequence up to 48 human whole genomes, producing 6Tb of data, per single run as short as 40 hours. To match NovaSeq’s high capacity and efficiency, Novogene also upgraded its data storage and computing power to 878T flops, total memory of 368TB, and total storage of 29PB.

Introduced by Illumina in January 2017, NovaSeq is a highly powerful sequencer designed to be scalable and flexible for virtually any genome, method, and scale of project. In human disease research, Novogene’s addition of the NovaSeq sequencing platform will enable the study of rare genetic variations with larger sample size, greater depth and faster speed, and accelerate the progress of global precision medical research.

“We were among the first to receive Illumina’s HiSeq X sequencers when they were first introduced, so we are pleased to now be among the first to adopt the new NovaSeq sequencing system,” stated Ruiqiang Li, Ph.D., Founder and CEO of Novogene. “We look forward to bringing the benefits of this powerful new sequencing system to our customers through affordable, flexible and scalable solutions for their diverse research needs.”

This article has been republished from materials provided by Novogene. Note: material may have been edited for length and content. For further information, please contact the cited source.